Moving Away From Standard Induction in Newly Diagnosed Acute Myeloid Leukemia As of April 2025, four CD19-directed chimeric antigen receptor (CAR)-T therapies and three CD20-targeting bispecific ...
Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced (armored) ...
Safety and efficacy of chimeric antigen receptor (CAR)–T cell therapy (BRG01) targeting the Epstein-Barr virus (EBV) envelope protein in EBV+ lymphoproliferative disease patients. Cumulative incidence ...
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...
Recent research indicates that the spatial architecture of membrane proteins is crucial for regulating T-cell signaling and activation. 3-5 In the context of CAR T cells, the nanoscale localization ...
Please provide your email address to receive an email when new articles are posted on . A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the ...
Immunotherapy has revolutionized cancer treatment by harnessing the power of T cells to attack tumors. But, even when these treatments are successful, scientists often struggle to understand exactly ...
Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...
Post-CAR T infection prophylaxis should follow European Hematology Association/European Society for Blood and Marrow ...
However, details of the intervening steps, as researchers have learned in the past 65 years, are quite complex — certain cells carry the flu antigen to the immune system, specific immune cells respond ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback